Chinese Consensus on Management of Tyrosine Kinase Inhibitor-associated Side Effects in Gastrointestinal Stromal Tumors

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2018 Dec 25

PMID 30581268

Citations 6

Authors

Jian Li

Ming Wang

Bo Zhang

Xin Wu

Tian-Long Lin

Xiu-Feng Liu

Ye Zhou

Xin-Hua Zhang

Hao Xu

Li-Jing Shen

Jing Zou

Ping Lu

Dong Zhang

Wei-Jun Gu

Mei-Xia Zhang

Jian Pan

Hui Cao

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Here, we present the resultant evidence- and experience-based consensus to guide the management of TKI-associated side events in clinical practice.

Citing Articles

Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis.

Jiang X, Xiong F, Fu Q, Peng H, Jing Y, Rexiti K Int J Colorectal Dis. 2022; 37(7):1525-1534.

PMID: 35780257 DOI: 10.1007/s00384-022-04214-7.

Imatinib-associated skin rash is related to treatment outcome in patients with unresectable and/or metastatic gastrointestinal stromal tumor.

Zhang M, Li L, Sun H, Tang T, Li Q, Chen L J Gastrointest Oncol. 2022; 13(1):117-125.

PMID: 35284105 PMC: 8899760. DOI: 10.21037/jgo-22-65.

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis.

Zhang C, Zhang C, Zhang T, Liu H, Zhong J, Wang Z Transl Cancer Res. 2022; 10(7):3206-3217.

PMID: 35116627 PMC: 8798138. DOI: 10.21037/tcr-21-613.

Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors.

Xu H, Liu Q Onco Targets Ther. 2021; 13:13345-13355.

PMID: 33456310 PMC: 7804055. DOI: 10.2147/OTT.S279998.

Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.

Wang J, Yin Y, Shen C, Yin X, Cai Z, Pu L Medicine (Baltimore). 2020; 99(9):e19275.

PMID: 32118738 PMC: 7478449. DOI: 10.1097/MD.0000000000019275.

References

Stahl J, COOK E, Graziano F, Barney N . Human conjunctival mast cells: expression of Fc epsilonRI, c-kit, ICAM-1, and IgE. Arch Ophthalmol. 1999; 117(4):493-7. DOI: 10.1001/archopht.117.4.493. View

Alexopoulos C, Vaslamatzis M, Hatzidimitriou G . Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999; 81(1):69-74. PMC: 2374347. DOI: 10.1038/sj.bjc.6690652. View

Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed R, Heldin C . Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001; 61(7):2929-34. View

Kurzrock R . The role of cytokines in cancer-related fatigue. Cancer. 2001; 92(6 Suppl):1684-8. DOI: 10.1002/1097-0142(20010915)92:6+<1684::aid-cncr1497>3.0.co;2-z. View

Gralla R . New agents, new treatment, and antiemetic therapy. Semin Oncol. 2002; 29(1 Suppl 4):119-24. DOI: 10.1053/sonc.2002.31535. View

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

Esmaeli B, Prieto V, Butler C, Kim S, Ahmadi M, Kantarjian H . Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002; 95(4):881-7. DOI: 10.1002/cncr.10729. View

Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H . Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002; 20(20):4271-2. DOI: 10.1200/JCO.2002.99.179. View

Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P . Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003; 48(2):201-6. DOI: 10.1067/mjd.2003.44. View

10.

Deininger M, OBrien S, Ford J, Druker B . Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003; 21(8):1637-47. DOI: 10.1200/JCO.2003.11.143. View

11.

Yang J, Haworth L, Sherry R, Hwu P, Schwartzentruber D, Topalian S . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-34. PMC: 2275324. DOI: 10.1056/NEJMoa021491. View

12.

Fraunfelder F, Solomon J, Druker B, Esmaeli B, Kuyl J . Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003; 19(4):371-5. DOI: 10.1089/108076803322279426. View

13.

Post-White J, Kinney M, Savik K, Gau J, Wilcox C, Lerner I . Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther. 2004; 2(4):332-44. DOI: 10.1177/1534735403259064. View

14.

. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5 Suppl 1):S1-290. View

15.

de Zeeuw D, Remuzzi G, Parving H, Keane W, Zhang Z, Shahinfar S . Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004; 65(6):2309-20. DOI: 10.1111/j.1523-1755.2004.00653.x. View

16.

Guilhot F . Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004; 9(3):271-81. DOI: 10.1634/theoncologist.9-3-271. View

17.

Cassileth B, Vickers A . Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage. 2004; 28(3):244-9. DOI: 10.1016/j.jpainsymman.2003.12.016. View

18.

Verweij J, Casali P, Zalcberg J, Lecesne A, Reichardt P, Blay J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-34. DOI: 10.1016/S0140-6736(04)17098-0. View

19.

Atkins R, Briganti E, Lewis J, Hunsicker L, Braden G, Champion de Crespigny P . Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005; 45(2):281-7. DOI: 10.1053/j.ajkd.2004.10.019. View

20.

Zalcberg J, Verweij J, Casali P, Cesne A, Reichardt P, Blay J . Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005; 41(12):1751-7. DOI: 10.1016/j.ejca.2005.04.034. View